354 reports of this reaction
1.1% of all CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE reports
#17 most reported adverse reaction
PULMONARY EMBOLISM is the #17 most commonly reported adverse reaction for CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE, manufactured by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.. There are 354 FDA adverse event reports linking CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE to PULMONARY EMBOLISM. This represents approximately 1.1% of all 33,191 adverse event reports for this drug.
Patients taking CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE who experience pulmonary embolism should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PULMONARY EMBOLISM is a less commonly reported adverse event for CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE, but still significant enough to appear in the safety profile.
In addition to pulmonary embolism, the following adverse reactions have been reported for CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE:
The following drugs have also been linked to pulmonary embolism in FDA adverse event reports:
PULMONARY EMBOLISM has been reported as an adverse event in 354 FDA reports for CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PULMONARY EMBOLISM accounts for approximately 1.1% of all adverse event reports for CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE, making it a notable side effect.
If you experience pulmonary embolism while taking CONJUGATED ESTROGENS AND MEDROXYPROGESTERONE ACETATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.